Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Cancer Ther Res ; 2: 21, 2013 Dec 28.
Artículo en Inglés | MEDLINE | ID: mdl-25520806

RESUMEN

In this study, we investigated the cytotoxic effects of a broad-spectrum histone deacetylase (HDAC) inhibitor, PCI-24781, alone and in combination with the proteasome inhibitor bortezomib in neuroblastoma cell lines. The combination was shown to induce synergistic cytotoxity involving the formation of reactive oxygen species. The cleavage of caspase-3 and PARP, as determined by western blotting, indicated that cell death was primarily due to apoptosis. Xenograft mouse models indicated increased survival among animals treated with this combination. The Notch signaling pathway and MYCN gene expression were quantified by reverse transcription-polymerase chain reaction (PCR) in cells treated with PCI-24781 and bortezomib, alone and in combination. Notch pathway expression increased in response to an HDAC inhibitor. NFKB1 and MYCN were both significantly down regulated. Our results suggest that PCI-24781 and bortezomib are synergistic in neuroblastoma cell lines and may be a new therapeutic strategy for this disease.

2.
Cancer Biol Ther ; 11(12): 1036-45, 2011 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-21532338

RESUMEN

Patients diagnosed with high-risk neuroblastoma (NB), an extracranial solid tumor in children, have metastases and low survival (30%) despite aggressive multi-modal therapy. Therefore new therapies are urgently needed. We show significant in vitro and in vivo antitumor efficacy of RKS262 in NB. RKS262 showed superior cytotoxicity (IC(50) = 6-25 µM) against six representative NB cell lines compared to its parent analog Nifurtimox (currently in phase 2). Pre-formulated RKS262 (150 mg/kg/daily) pellets administered orally, suppressed tumor growth (60%, p = 0.021) in NB xenograft mice within 28 days. RKS262-treated SMSKCNR cells showed TUNEL-positive DNA nicks and activation of ROS, MAPKs (SAPK/JNK), caspase-3, and p53, along with suppression of the IGF-1R/PI3K/PKC pathway and the Bcl2 family of proteins. RKS262 caused G(2)/M-phase arrest and suppressed cdc-2, cyclin B1, p21, and cyclin D1/D4 expression. N-acetyl-cysteine (NAC; 10 mM) pre-treatment rescued cell viability of RKS262 (23 µM)-treated SMSKCNR cells, and pre-treatment with ascorbic acid (100 µM) and a MAPK inhibitor SB203580 (20 µM) reversed SAPK/JNK, caspase-3 activation, PARP-1 cleavage, and suppression of IGF-1R, PI3K, and PKC phosphorylation. Further, treatment with exogenous BDNF (50 nM) did not suppress SAPK/JNK or ROS activation due to RKS262. Rather, BDNF (50 nM), EGF (100 nM) and IGF-1 (100 nM) co-treatment with RKS262 induced a remarkable S-phase arrest rather than a G(2)/M phase arrest when RKS262 was used alone. In summary, RKS262 shows oral efficacy in NB xenograft animals, and induces apoptosis in vitro in SMSKCNR cells via cell cycle arrest, MAPK and ROS activation, and suppression of IGF-1R/PI3K/PKC and Bcl2 family proteins in a growth factor (BDNF/EGF/IGF-1)-independent fashion.


Asunto(s)
Antineoplásicos/farmacología , Cumarinas/farmacología , Óxidos S-Cíclicos/farmacología , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Neuroblastoma/metabolismo , Neuroblastoma/patología , Especies Reactivas de Oxígeno/metabolismo , Carga Tumoral/efectos de los fármacos , Administración Oral , Animales , Antineoplásicos/química , Apoptosis/efectos de los fármacos , Factor Neurotrófico Derivado del Encéfalo/farmacología , Caspasa 3/metabolismo , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Cumarinas/administración & dosificación , Cumarinas/química , Óxidos S-Cíclicos/administración & dosificación , Óxidos S-Cíclicos/química , Factor de Crecimiento Epidérmico/farmacología , Femenino , Humanos , Factor I del Crecimiento Similar a la Insulina/farmacología , Ratones , Ratones Desnudos , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Int J Oncol ; 38(5): 1329-41, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21399873

RESUMEN

Medulloblastoma, a neuroectodermal tumor arising in the cerebellum, is the most common brain tumor found in children. We recently showed that nifurtimox induces production of reactive oxygen species (ROS) and subsequent apoptosis in neuroblastoma cells both in vitro and in vivo. Tetrathiomolybdate (TM) has been shown to decrease cell proliferation by inhibition of superoxide dismutase-1 (SOD1). Since both nifurtimox and TM increase ROS levels in cells, we investigated whether the combination of nifurtimox and TM would act synergistically in medulloblastoma cell lines (D283, DAOY). Genome-wide transcriptional analysis, by hybridizing RNA isolated from nifurtimox and TM alone or in combination treated and control cells (D283) on Affymetrix exon array gene chips was carried out to further confirm synergy. We show that nifurtimox and TM alone and in combination decreased cell viability and increased ROS levels synergistically. Examination of cell morphology following drug treatment (nifurtimox + TM) and detection of caspase-3 activation via Western blotting indicated that cell death was primarily due to apoptosis. Microarray data from cells treated with nifurtimox and TM validated the induction of oxidative stress, as many Nrf2 target genes (HMOX1, GCLM, SLC7A11 and SRXN1) (p<10(-5)) were upregulated. Other genes related to apoptosis, oxidative stress, DNA damage, protein folding and nucleosome formation were differentially involved in cells following treatment with nifurtimox + TM. Taken together, our results suggest nifurtimox and TM act synergistically in medulloblastoma cells in vitro, and that this combination warrants further studies as a new treatment for medulloblastoma.


Asunto(s)
Neoplasias Cerebelosas/tratamiento farmacológico , Meduloblastoma/tratamiento farmacológico , Molibdeno/farmacología , Nifurtimox/farmacología , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Neoplasias Cerebelosas/patología , Daño del ADN , Sinergismo Farmacológico , Humanos , Meduloblastoma/metabolismo , Meduloblastoma/patología , Factor 2 Relacionado con NF-E2/fisiología , Especies Reactivas de Oxígeno/metabolismo
4.
Methods Mol Biol ; 383: 153-63, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-18217684

RESUMEN

Bacterial artificial chromosomes (BACs) provide a well-characterized resource for studying the organization and activity of entire genes, replicons, and other large genomic loci. Protocols and parameters that influence the efficient transfection of these large DNA molecules into cells in culture were described here. By carefully optimizing the conditions for the formation of compact transfection complexes, BACs can be introduced into a variety of mammalian cells with reasonable efficiency. In addition, by cotransfection with a dihydrofolate reductase or hypoxanthine guanine phosphoribosyl transferase BAC, stable cell lines can be generated that carry 2-15 tandem chromosomal copies of the BAC of interest, thus providing a new avenue for studying gene dosage effects.


Asunto(s)
Cromosomas Artificiales Bacterianos , Dosificación de Gen , Transfección , Línea Celular , Humanos
5.
Genomics ; 83(1): 66-75, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14667810

RESUMEN

Bacterial artificial chromosomes (BACs) provide a well-characterized resource for studying the functional organization of genes and other large chromosomal domains. To facilitate functional studies in cell cultures, we have developed a simple approach for generating stable cell lines with variable copy numbers of any BAC. Here we describe hamster cell lines with BAC transgenes that express mouse Cdc6 at levels that correlate with BAC copy number; show that mouse Cdc6 is regulated normally during the cell cycle, binds chromatin, and is degraded during apoptosis; and report a novel fraction of Cdc6 that associates with the spindle apparatus during mitosis. With RNA interference to assess genetic complementation by BAC alleles, this system will facilitate functional studies on large chromosomal domains at variable copy number in mammalian cell models.


Asunto(s)
Proteínas de Ciclo Celular/genética , Cromosomas Artificiales Bacterianos/genética , Proteínas de Saccharomyces cerevisiae/genética , Huso Acromático/metabolismo , Animales , Células CHO , Ciclo Celular/fisiología , Proteínas de Ciclo Celular/metabolismo , División Celular/fisiología , Cromatina/metabolismo , Cricetinae , Cricetulus , Electroforesis en Gel de Poliacrilamida , Regulación de la Expresión Génica , Immunoblotting , Ratones , Microscopía Fluorescente , Unión Proteica , Interferencia de ARN , ARN Interferente Pequeño/genética , Proteínas de Saccharomyces cerevisiae/metabolismo , Factores de Tiempo , Transfección , Transgenes/genética
6.
Biotechniques ; 35(4): 796-807, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14579745

RESUMEN

Although bacterial artificial chromosomes (BACs) provide a well-characterized resource for the analysis of large chromosomal domains, low transfection rates have proven a significant limitation for their use in cell culture models. Using TP53 BAC clones that contain expression cassettes for enhanced green fluorescent protein or red fluorescent protein, we have examined conditions that promote BAC transfection in hamster, human, and mouse cell lines. Atomic force microscopy shows that BAC transfection efficiency correlates with the generation of small, highly condensed but dispersed lipid: BAC DNA transfection complexes. BAC DNA purity and concentration are critical for good transfection; debris from purification columns induces the formation of large aggregates that do not gain entry into the cell, and DNA concentrations must be optimized to promote intramolecular condensation rather than intermolecular linking, which also causes aggregation and diminished transfection efficiency. The expression of both markers and genes within BACs initially occurs at lower levels than observed with plasmids, requiring 3-5 days to evaluate the transfection results. We also show that BACs can be co-transfected with other BACs, which provides for increased experimental flexibility.


Asunto(s)
Cromosomas Artificiales Bacterianos/genética , Cromosomas Artificiales Bacterianos/ultraestructura , Perfilación de la Expresión Génica/métodos , Transfección/métodos , Animales , Línea Celular , Cricetinae , Cricetulus , Humanos , Mamíferos , Ratones , Osteosarcoma/genética , Osteosarcoma/ultraestructura , Control de Calidad , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA